Can paroxetine (often misspelled "laroxetine") taken by a breastfeeding mother cause mitral valve problems in the infant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Paroxetine During Breastfeeding Does NOT Cause Mitral Valve Problems in Infants

Paroxetine is considered relatively safe during breastfeeding and does not cause mitral valve issues in breastfed infants. The cardiac malformation concerns associated with paroxetine are specific to first-trimester pregnancy exposure, not breastfeeding exposure 1, 2.

Key Evidence on Breastfeeding Safety

Paroxetine transfers into breast milk in very low concentrations - breastfed infants receive less than 3% of the weight-adjusted maternal dose, and it is present in very low concentrations in infant plasma 1, 3. This minimal exposure is fundamentally different from the direct fetal exposure during pregnancy that raises cardiac concerns.

The 2026 Indian Journal of Psychiatry guidelines explicitly state that "sertraline, fluvoxamine, and paroxetine are present in very low concentrations in the plasma of breast-fed infants (<3% of the maternal dose). It is surmised that they are relatively safe during breastfeeding" 1.

Why the Confusion Exists

The cardiac malformation risk you may have heard about applies only to first-trimester pregnancy exposure, not breastfeeding:

  • During pregnancy: Paroxetine crosses the placenta during fetal cardiac development (first trimester) and has been associated with increased risk of cardiac septal defects (VSDs and ASDs), with absolute risk of 1.5-2% versus 1% in the general population 1, 2
  • During breastfeeding: The drug exposure is minimal (<3% of maternal dose), occurs after cardiac development is complete, and has no documented association with valve problems 1

What to Monitor in Breastfed Infants

While mitral valve issues are not a concern, breastfed infants exposed to paroxetine should be monitored for:

  • Serotonergic toxicity symptoms (irritability, poor feeding, tremor)
  • Antidepressant discontinuation symptoms
  • General feeding and sleep patterns 1

Clinical Bottom Line

If you are breastfeeding and taking paroxetine, you do not need to worry about causing mitral valve problems in your baby. The cardiac risks are pregnancy-specific and do not apply to breastfeeding. Paroxetine remains one of the preferred SSRIs during lactation due to its low milk transfer 4, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.